AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Neuropace, Inc. Common Stock
XNAS · usd
SIC 3841 · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
FIGI BBG001V0SVB1
12.91▼ 0.23 (-1.75%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
13.14
Day's Range
12.76 – 13.07
52-Week Range
9.22 – 19.60
Volume
69.1K
Avg Volume
122.2K
Share Statistics
Shares Outstanding
Employees
209
Exchange
XNAS
Listed
2021-04-22
Share count as of August 7, 2026

Neuropace, Inc. Common Stock (NPCE) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Neuropace, Inc. Common Stock (NPCE)
What is Neuropace, Inc. Common Stock's Market Cap?
Neuropace, Inc. Common Stock's Market Cap is $443.1M, based on as-reported figures from SEC (XBRL) filings.
What is Neuropace, Inc. Common Stock's Enterprise Value?
Neuropace, Inc. Common Stock's Enterprise Value is $450.4M, based on as-reported figures from SEC (XBRL) filings.
What is Neuropace, Inc. Common Stock's Price / Sales?
Neuropace, Inc. Common Stock's Price / Sales is 4.1×, based on as-reported figures from SEC (XBRL) filings.
What is Neuropace, Inc. Common Stock's EV / Revenue?
Neuropace, Inc. Common Stock's EV / Revenue is 4.2×, based on as-reported figures from SEC (XBRL) filings.
What is Neuropace, Inc. Common Stock's EV / EBITDA?
Neuropace, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Neuropace, Inc. Common Stock's Revenue (TTM)?
Neuropace, Inc. Common Stock's Revenue (TTM) is $107.0M, based on as-reported figures from SEC (XBRL) filings.
What is Neuropace, Inc. Common Stock's Net Income (TTM)?
Neuropace, Inc. Common Stock's Net Income (TTM) is -$19.1M, based on as-reported figures from SEC (XBRL) filings.
What is Neuropace, Inc. Common Stock's EBITDA?
Neuropace, Inc. Common Stock's EBITDA is -$11.9M, based on as-reported figures from SEC (XBRL) filings.
What is Neuropace, Inc. Common Stock's Diluted EPS (TTM)?
Neuropace, Inc. Common Stock's Diluted EPS (TTM) is -0.56, based on as-reported figures from SEC (XBRL) filings.
What is Neuropace, Inc. Common Stock's EBITDA Margin?
Neuropace, Inc. Common Stock's EBITDA Margin is -11.1%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · NPCEAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
YoY growth+17.1%-2.0%+23.9%+29.9%
Cost of goods sold
Gross profit
% of revenue82.8%81.8%77.4%77.4%
Operating expenses:
Sales and marketing
Research and development
General and administrative
Total operating expenses
% of revenue105.4%107.0%84.0%86.9%
Loss from continuing operations
% of revenue-22.5%-25.2%-6.6%-9.5%
Interest income
Interest expense
Other income (expense), net
Net loss and comprehensive loss from continuing operations———
Net loss and comprehensive loss
% of revenue-27.2%-30.3%-10.3%-12.8%
Net loss per share from continuing operations attributable to common stockholders, basic (in dollars per share)———
Net loss per share from continuing operations attributable to common stockholders, diluted (in dollars per share)———
Net income per share from discontinued operations attributable to common stockholders, basic (in dollars per share)———
Net income per share from discontinued operations attributable to common stockholders, diluted (in dollars per share)———
Net loss per share attributable to common stockholders, basic (in dollars per share)
Net loss per share attributable to common stockholders, diluted(in dollars per share)